Alkermes plc. revenue
Alkermes plc.'s revenue was $1.48bn in fiscal 2025, down 5.2% on the year before. Since fiscal 2010 ($178m) it has grown at a compound 15.1% a year. Over the last twelve months it was $1.75bn.
Revenue history
| Fiscal year | 2010Mar 2010 | 2011Mar 2011 | 2012Mar 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 178 | 187 | 390 | 596 | 619 | 628 | 746 | 903 | 1,094 | 1,171 | 1,039 | 1,174 | 1,112 | 1,663 | 1,558 | 1,476 | 1,754 |
| Growth on the year before | — | +4.7% | +108.9% | +52.9% | +3.8% | +1.5% | +18.7% | +21.1% | +21.1% | +7.0% | −11.3% | +13.0% | −5.3% | +49.6% | −6.4% | −5.2% | — |
| Gross profit | — | — | — | — | — | — | 614 | 749 | 918 | 991 | 860 | 976 | 894 | 1,410 | 1,312 | 1,279 | 1,453 |
| Gross margin | — | — | — | — | — | — | 82.3% | 82.9% | 83.9% | 84.6% | 82.8% | 83.2% | 80.4% | 84.8% | 84.2% | 86.7% | 82.9% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $1.2B | 80.3% | ▲ 9.3% |
| Vivitrol (part of Products) | $468M | 39.5% | ▲ 2.3% |
| Aristada and Aristada Initio (part of Products) | $370M | 31.2% | ▲ 6.9% |
| LYBALVI (part of Products) | $347M | 29.3% | ▲ 23.8% |
| Manufactured Product and Royalty | $291M | 19.7% | ▼ 38.6% |
| Royalty (part of Manufactured Product and Royalty) | $245M | 84.2% | ▼ 30.8% |
| Manufacturing Revenue (part of Manufactured Product and Royalty) | $46M | 15.8% | ▼ 61.5% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $1.4B | 93.0% | ▼ 2.7% |
| Foreign Country Excluding Specified Country | $102M | 6.9% | ▼ 30.0% |
| Ireland | $754,000 | 0.1% | ▼ 41.7% |
From Alkermes plc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Alkermes plc. | $1.75bn | 15.3% | 3.3% |
| Halozyme Therapeutics, Inc. | $1.66bn | 41.2% | 29.1% |
| Insmed Inc | $1.52bn | 240.0% | 75.6% |
| Madrigal Pharmaceuticals, Inc. | $1.43bn | 92.8% | — |
| Moderna | $2.23bn | -27.6% | -40.6% |
| Lakefront Biotherapeutics NV | $1.26bn | 321.6% | — |
Compare with peers
- Halozyme Therapeutics, Inc. revenue
- Insmed Inc revenue
- Madrigal Pharmaceuticals, Inc. revenue
- Moderna revenue
- Lakefront Biotherapeutics NV revenue
Head to head: ALKS vs HALOALKS vs INSMALKS vs MDGLALKS vs MRNA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies